 CF product revenues grew by 18 in Q3 of 2022 to 2.33 billion. TRIKAFTA continues uptake in the U.S. but larger 49 sales growth was observed in territories outside of the U.S. VX-522 is being developed in collaboration with Moderna to treat 5,000 Cystic Fibrosis patients who do not currently respond to CFTR drugs available. Goal to replace functional CFTR gene. 